Back to Journals » Clinical Epidemiology » Volume 5 » Issue 1

Global incidence and outcome of testicular cancer

Authors Shanmugalingam T, Soultati A, Chowdhury S, Rudman S, Van Hemelrijck M 

Received 23 April 2013

Accepted for publication 18 June 2013

Published 17 October 2013 Volume 2013:5(1) Pages 417—427

DOI https://doi.org/10.2147/CLEP.S34430

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4



Thurkaa Shanmugalingam,1 Aspasia Soultati,2 Simon Chowdhury,2 Sarah Rudman,2 Mieke Van Hemelrijck1

1King’s College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, UK; 2Department of Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Background: Testicular cancer is a rare tumor type accounting for 1% of malignancies in men. It is, however, the most common cancer in young men in Western populations. The incidence of testicular cancer is increasing globally, although a decline in mortality rates has been reported in Western countries. It is important to identify whether the variations in trends observed between populations are linked to genetic or environmental factors.
Methods: Age-standardized incidence rates and age-standardized mortality rates for testicular cancer were obtained for men of all ages in ten countries from the Americas, Asia, Europe, and Oceania using the Cancer Incidence in Five Continents (CI5plus) and World Health Organization (WHO) mortality databases. The annual percent change was calculated using Joinpoint regression to assess temporal changes between geographical regions.
Results: Testicular cancer age-standardized incidence rates are highest in New Zealand (7.8), UK (6.3), Australia (6.1), Sweden (5.6), USA (5.2), Poland (4.9), and Spain (3.8) per 100,000 men. India, People’s Republic of China, and Colombia had the lowest incidence (0.5, 1.3, and 2.2, respectively) per 100,000 men. The annual percent changes for overall testicular cancer incidence significantly increased in the European countries Sweden 2.4%, (2.2; 2.6); UK 2.9%, (2.2; 3.6); and Spain 5.0%, (1.7; 8.4), Australia 3.0%, (2.2; 3.7), and People’s Republic of China 3.5%, (1.9; 5.1). India had the lowest overall testicular cancer incidence -1.7%, (-2.5; -0.8). Annual percent changes for overall testicular cancer mortality rates were decreasing in all study populations, with the greatest decline observed in Sweden -4.2%, (-4.8; -3.6) and People’s Republic of China -4.9%, (-6.5; -3.3).
Conclusion: Testicular cancer is increasing in incidence in many countries; however, mortality rates remain low and most men are cured. An understanding of the risks and long-term side effects of treatment are important in managing men with this disease.

Keywords: testicular cancer, global, incidence, mortality

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.